@article {Golan2022.12.12.22283367, author = {Yarden Golan and Mikias Ilala and Caryl Gay and Soumya Hunagund and Christine Y. Lin and Arianna G. Cassidy and Unurzul Jigmeddagva and Lin Li and Nida Ozarslan and Ifeyinwa V. Asiodu and Nadav Ahituv and Valerie J. Flaherman and Stephanie L. Gaw and Mary Prahl}, title = {Milk antibody response after 3rd dose of COVID-19 mRNA vaccine and SARS-CoV-2 breakthrough infection and implications for infant protection}, elocation-id = {2022.12.12.22283367}, year = {2022}, doi = {10.1101/2022.12.12.22283367}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Anti-SARS-CoV-2 antibodies have been found in human-milk after COVID-19 infection and vaccination. However, little is known about their persistence in milk after booster vaccination and breakthrough infection. In this study, human-milk, saliva and blood samples were collected from 33 lactating individuals before and after mRNA-based vaccination and COVID-19 breakthrough infections. Antibody levels were measured using ELISA and symptoms were assessed using questionnaires. Evaluation of maternal and infant symptomatology revealed that infected mothers reported more symptoms than vaccinated mothers. We found that after vaccination, human-milk anti-SARS-CoV-2 antibodies persisted for up to 8 months. In addition, distinct patterns of human milk IgA and IgG production we observed after breakthrough infection compared to 3-dose vaccination series alone, indicating a differential central and mucosal immune profiles in hybrid compared with vaccine-induced immunity. To investigate passively-derived milk antibody protection in infants, we examined the persistence of these antibodies in infant saliva after breastfeeding. We found that IgA was more abundant in infant saliva compared to IgG and persist in infant saliva longer after feeding. Our results delineate the differences in milk antibody response to vaccination as compared to breakthrough infection and emphasize the importance of improving the secretion of IgA antibodies to human milk after vaccination to improve the protection of breastfeeding infants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementY.G. was supported by the Weizmann Institute of Science - National Postdoctoral Award Program for Advancing Women in Science, and of the Human Frontiers in Science Program (HFSP). M.P. was supported by the National Institutes of Health (NIAID K23AI127886), the Marino Family Foundation, and UCSF REAC award. S.L.G. was supported by the National Institutes of Health (NIAID K08AI141728).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board of the University of California, San Francisco, approved the study ($\#$21-33621). Written informed consent was obtained from all study volunteers as part of the COVID-19 Vaccine in Pregnancy and Lactation (COVIPAL) cohort study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors}, URL = {https://www.medrxiv.org/content/early/2022/12/14/2022.12.12.22283367}, eprint = {https://www.medrxiv.org/content/early/2022/12/14/2022.12.12.22283367.full.pdf}, journal = {medRxiv} }